Format

Send to

Choose Destination
Cleve Clin J Med. 2017 Dec;84(12 Suppl 3):12-26. doi: 10.3949/ccjm.84.s3.02.

Cardiac amyloidosis: An update on diagnosis and treatment.

Author information

1
Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.
2
Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA. hannam@ccf.org.

Abstract

Cardiac amyloidosis (CA), once thought to be a rare disease, is increasingly recognized due to enhanced clinical awareness and better diagnostic imaging. CA is becoming of heightened interest to the cardiology community given more effective treatment strategies for light chain amyloidosis (AL), as well as emerging therapies for transthyretin amyloidosis (ATTR). Furthermore, reversing amyloid deposition in affected organs using monoclonal antibodies is actively being tested in clinical trials. A high index of suspicion and a systematic approach to the diagnosis of CA can lead to referral to a center of expertise for timely treatment.

PMID:
29257735
DOI:
10.3949/ccjm.84.s3.02
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Cleveland Clinic
Loading ...
Support Center